Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Jason R. Westin(The University of Texas MD Anderson Cancer Center), Frederick L. Locke(Moffitt Cancer Center), Lori A. Leslie(Hackensack University Medical Center), Marco Schupp(Amgen (Switzerland)), Matthew L. Ulrickson, Yin Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Marie José Kersten(Hovon), Kathleen Dorritie(University of Pittsburgh), Simone Filosto(Kite (United States)), Caron A. Jacobson(Dana-Farber Cancer Institute), Olalekan O. Oluwole(Vanderbilt University), Tom van Meerten(University Medical Center Groningen), Monique C. Minnema(University Medical Center Utrecht), Joseph P. McGuirk(University of Kansas Medical Center), Saran Vardhanabhuti, Shilpa Shahani(City of Hope), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Patrick M. Reagan(University of Rochester), Aaron P. Rapoport(University of Maryland, Baltimore), Christina To, Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Armin Ghobadi(Washington University in St. Louis), Paul Cheng(Cardiovascular Institute of the South), Umar Farooq(Wake Forest University), Michael Dickinson(The University of Melbourne), Kevin Song(Vancouver General Hospital), David B. Miklos(Stanford University), Mahmoud Elsawy(Dalhousie University), Sridhar Chaganti(Cutaneous Lymphoma Foundation), Peter A. Riedell(University of Chicago)
Cited by 437
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k